Wegovy Ads — What UK Law Allows, and What That Means for You

Why you can't see a Wegovy TV ad, and why that's actually protecting you

The UK draws a firm line between advertising prescription medicines and educating people about them. That line exists for good reason. A television campaign for a POM could reach people for whom the medicine is contraindicated, inappropriate, or genuinely dangerous. So the MHRA prohibits direct-to-consumer advertising of any prescription-only medicine, Wegovy included. This is not a gap in marketing budgets; it's a legal restriction.

What you will see, legitimately, is branded awareness around the condition of obesity, the existence of clinical pathways, or general signposting to speak with a healthcare professional. Novo Nordisk can talk about weight management as a health issue. They cannot run a campaign that tells you to go and buy Wegovy. That distinction matters because it changes how you should read anything that does appear to be selling you this medicine directly.

If a social media post, website or text message is actively encouraging you to purchase semaglutide without first directing you to a clinical assessment, treat it with serious scepticism. The MHRA has repeatedly warned about counterfeit and illegally traded weight-loss pens, large seizures of fake products have been made from unregulated online sellers, and some of those fakes have caused harm. Reporting suspected illegal sellers via the MHRA's Yellow Card scheme is straightforward and genuinely useful.

What a compliant UK Wegovy page can tell you, and where the gaps are

Understanding what regulated providers can legally say helps you assess what you're reading. A GPhC-registered pharmacy can describe, factually, that Wegovy is a once-weekly semaglutide injection licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related health condition. It can describe the general trial evidence, the STEP 1 study, published in the New England Journal of Medicine, reported an average body-weight reduction of around 15% over 68 weeks at the 2.4mg maintenance dose. It can explain the clinical process: a prescriber reviews your consultation; if the medicine is appropriate, it's dispensed through the licensed supply chain.

What it cannot do is urge you to order now, imply approval is guaranteed, make claims about how much weight you personally will lose, or price-lead in a way designed to drive impulse purchases of a prescription medicine. If a page you're reading does any of those things, the compliance picture is not clean.

Curious about what treatment involves from start to finish? The overview of Wegovy at nume walks through the licensed indications and what the consultation process actually looks like, without the sales pressure that shouldn't be there in the first place.

The decision you're actually making, and what legitimate information looks like

Most people searching for Wegovy ads aren't looking for a commercial, they're trying to work out whether this is real, whether it's right for them, and whether they can trust what they're reading. Those are the right questions.

Real information about Wegovy comes from the NHS, NICE, the MHRA, and clinical services that operate under those regulators. NICE's appraisal of semaglutide (TA875) is publicly available and readable, it sets out who the medicine is recommended for, what the evidence shows, and what the clinical conditions of use are. That's the kind of source worth reading before anything else.

For most people, the actual decision is whether to start a consultation with a regulated service. At a legitimate provider, that consultation is reviewed by a real prescriber, a GPhC-registered Independent Prescriber who looks at your health picture, not a piece of software making an automated call. If the medicine is clinically suitable, it's prescribed and dispensed through the authorised UK supply chain. At nume (at our pharmacy, which is GPhC-registered (premises registration 9012878, verifiable at pharmacyregulation.org)) your order arrives via DPD the next working day in plain, unbranded packaging. The pen itself is a pre-filled Novo Nordisk device; there's nothing unfamiliar about it when it arrives.

Cost is a reasonable part of that decision too. Private Wegovy treatment is priced monthly, and the full picture of what's included (or excluded) varies by provider. The Wegovy cost page sets out the market context honestly, including what a transparent price should cover.

What to do if you've seen a Wegovy ad that doesn't feel right

A legitimate Wegovy-related communication from a regulated UK service will direct you to a clinical consultation as the first step. It will not offer the medicine at a price that seems implausibly low, promise results, or suggest you can skip any kind of medical review. If something you've seen does those things, it's worth pausing.

The MHRA's guidance on GLP-1 medicines is clear that these are serious prescription medicines, assessed for weight management under defined clinical criteria, not quick fixes available to anyone who clicks a link. Sellers operating without proper licensing, dispensing these medicines without a prescription, represent a patient safety risk. Report them via Yellow Card.

If you're trying to work out whether Wegovy could be appropriate for you, the right starting point is a proper clinical assessment. Treatment begins at the 0.5mg starting dose of Wegovy, before stepping up through the dose schedule, and you can read about what the 1mg stage of Wegovy involves as well as what to expect when you reach the 2mg dose further into treatment. Take a look at what the semaglutide treatment pathway involves, or explore the weight-loss treatment options available through a regulated UK pharmacy. When you're ready, you can check your eligibility by starting a free consultation at our treatment page, no obligation, reviewed the same day by a named prescriber.